Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
Angiotensin I
/ administration & dosage
Angiotensin II
/ administration & dosage
Animals
Cardiomegaly
/ metabolism
Disease Models, Animal
Fibrosis
Hypertension
/ chemically induced
Imidazoles
/ administration & dosage
Injections, Intraperitoneal
Losartan
/ administration & dosage
Male
Peptide Fragments
/ administration & dosage
Proto-Oncogene Mas
/ metabolism
Rats
Rats, Sprague-Dawley
Sulfonamides
/ administration & dosage
Thiophenes
/ administration & dosage
Tyrosine 3-Monooxygenase
/ metabolism
AT2 receptor agonist
angiotensin 1-7
angiotensin II
hypertension
myocardial fibrosis
myocardial hypertrophy
rats
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
30
11
2021
revised:
15
12
2021
accepted:
16
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
29
1
2022
Statut:
epublish
Résumé
Compound 21 (C21), an AT2 receptor agonist, and Angiotensin 1-7 (Ang 1-7), through Mas receptor, play an important role in the modulation of the protective arm of the renin-angiotensin system. The aim of this study was to investigate in an experimental model of angiotensin II-dependent hypertension whether the activation of the potentially protective arm of the renin-angiotensin system, through AT2 or Mas receptor stimulation, counteracts the onset of myocardial fibrosis and hypertrophy, and whether these effects are mediated by inflammatory mechanism and/or sympathetic activation. Sprague Dawley rats (
Identifiants
pubmed: 34948475
pii: ijms222413678
doi: 10.3390/ijms222413678
pmc: PMC8708804
pii:
doi:
Substances chimiques
Imidazoles
0
Peptide Fragments
0
Proto-Oncogene Mas
0
Sulfonamides
0
Thiophenes
0
Angiotensin II
11128-99-7
Angiotensin I
9041-90-1
Tyrosine 3-Monooxygenase
EC 1.14.16.2
angiotensin I (1-7)
IJ3FUK8MOF
Losartan
JMS50MPO89
compound 21
RC2V4W0EYC
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Acta Diabetol. 2021 Aug;58(8):1059-1070
pubmed: 33760995
Acta Physiol (Oxf). 2019 Sep;227(1):e13280
pubmed: 30957953
J Clin Med. 2020 Jan 18;9(1):
pubmed: 31963731
Circulation. 2008 Dec 9;118(24):2523-32
pubmed: 19029468
Hypertension. 2014 Mar;63(3):e60-7
pubmed: 24379181
Clin Exp Pharmacol Physiol. 2016 Mar;43(3):335-42
pubmed: 26700017
Circ Heart Fail. 2014 Mar 1;7(2):327-39
pubmed: 24389129
Br J Pharmacol. 2013 Jun;169(3):477-92
pubmed: 23488800
Nephrol Dial Transplant. 2006 Jan;21(1):16-20
pubmed: 16280370
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2417-23
pubmed: 16415071
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Acta Diabetol. 2019 Jan;56(1):97-104
pubmed: 30187136
Hypertension. 2012 Feb;59(2):291-9
pubmed: 22184324
Hypertension. 2014 Aug;64(2):378-83
pubmed: 24842923
Clin Sci (Lond). 2014 Jun;126(12):815-27
pubmed: 24593683
Circulation. 2003 Aug 5;108(5):560-5
pubmed: 12847071
Nat Rev Cardiol. 2020 Feb;17(2):116-129
pubmed: 31427727
Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H736-42
pubmed: 17098828
Hypertension. 2012 Feb;59(2):485-92
pubmed: 22215717
Int J Mol Sci. 2016 Jun 23;17(7):
pubmed: 27347925
Circ Res. 2015 Mar 13;116(6):960-75
pubmed: 25767283
J Hypertens. 2009 Dec;27(12):2444-51
pubmed: 19680135
Circulation. 2007 Feb 20;115(7):888-95
pubmed: 17283265
Hypertension. 2011 Feb;57(2):308-13
pubmed: 21189405
Cells. 2020 Dec 31;10(1):
pubmed: 33396359
Am J Physiol Heart Circ Physiol. 2017 May 1;312(5):H980-H991
pubmed: 28411231
Atherosclerosis. 2015 Jun;240(2):544-9
pubmed: 25957120
Eur J Heart Fail. 2008 Jun;10(6):534-9
pubmed: 18502686
Nutr Metab Cardiovasc Dis. 2019 Mar;29(3):301-305
pubmed: 30642787
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H666-72
pubmed: 17213482
Circulation. 2000 Jul 25;102(4):470-9
pubmed: 10908222
Biosci Rep. 2016 Nov 3;36(6):
pubmed: 27679859
J Exp Pharmacol. 2010 Nov 15;2:163-8
pubmed: 27186102
Physiol Rev. 2018 Jul 1;98(3):1627-1738
pubmed: 29873596
Curr Opin Pharmacol. 2015 Apr;21:115-21
pubmed: 25677800
Can J Cardiol. 2020 May;36(5):683-693
pubmed: 32389341
Am J Physiol Heart Circ Physiol. 2012 Jun 1;302(11):H2372-80
pubmed: 22467306